The Central Laboratories arm of ICON, the global provider of outsourced development services based in Ireland, has launched a global Cytometry Services offering through its facilities in New York (US), Dublin (Ireland), Bangalore (India) and Singapore.
The new full-service solution consists of two strands tailored to the particular testing requirements and development phase of a client’s compound.
Clients can work with ICON during the early stages of product development to create compound-specific assays. The ICON Central Laboratories R&D team will collaborate on developing a unique Flow Cytometry methodology, customised standard operating procedures and other special requirements including reporting, the company said.
These customised Flow Cytometry panels can then be used throughout the compound development lifecycle, it added.
ICON Cytometry Services’ other offering gives clients the choice of a wide range of fully validated assays and “is often suited to the large scale, high-volume requirements of later phase global trials”, the company noted.
Flow Cytometry “has become a preferred testing method for many of our clients, particularly those with autoimmune, oncology and immunodeficiency compounds that require more specialised testing”, pointed out Tom O’Leary, president of ICON Central Laboratories.